Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immune cell levels may predict who will develop severe CMV after transplant

NCT ID NCT07688759

Recruiting now Knowledge-focused Sponsor: The First Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study looks at how well the immune system recovers its ability to fight cytomegalovirus (CMV) in adults who have had a stem cell transplant. Researchers will measure special immune cells called CMV-specific T cells at several points during standard anti-CMV treatment. The goal is to see if low levels of these cells can predict which patients will go on to have severe or hard-to-treat CMV infections. If so, doctors could one day tailor treatment earlier for those at highest risk.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Anti-Cytomegalovirus Therapy (ganciclovir, valganciclovir, foscarnet, maribavir, or other approved anti-CMV medications)
What this could lead to
If successful, this could help doctors identify high-risk patients early and personalize treatment to prevent severe or persistent CMV infection after stem cell transplant.
What could go wrong
This is a small, exploratory study with only 40 participants, so findings may not apply to all patients. It measures immune markers, not direct treatment outcomes, so clinical benefit is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cytomegalovirus infection immune reconstitution inflammatory syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYTOMEGALOVIRUS INFECTIONS HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IMMUNE RECONSTITUTION

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital of Soochow University

    RECRUITING

    Suzhou, Jiangsu, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.